LEXX (Lexaria Bioscience) Cyclically Adjusted PS Ratio: (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEXX Lexaria Bioscience Corp LEXX
22 GF Score
Price $0.54
GF Value $0.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lexaria Bioscience Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lexaria Bioscience  (NAS:LEXX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Lexaria Bioscience Cyclically Adjusted PS Ratio Related Terms


Lexaria Bioscience Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience Cyclically Adjusted PS Ratio Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.31 12.00 0.00 44.96 9.89

Lexaria Bioscience Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.57 9.89 0.00 7.79 0.00

LEXX vs CTXR, PTN, HIND: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Lexaria Bioscience's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Cyclically Adjusted PS Ratio falls into.


LEXX
22GF Score
Lexaria Bioscience Corp LEXX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexaria Bioscience Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lexaria Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in May. 2026 is calculated as:

For example, Lexaria Bioscience's adjusted Revenue per Share data for the three months ended in May. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of May. 2026 (Change)*Current CPI (May. 2026)
=0/134.0005*134.0005
=0.000

Current CPI (May. 2026) = 134.0005.

Lexaria Bioscience Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201608 0.006 101.686 0.008
201611 0.005 101.607 0.007
201702 0.007 102.476 0.009
201705 0.014 103.108 0.018
201708 0.006 103.108 0.008
201711 0.011 103.740 0.014
201802 0.073 104.688 0.093
201805 0.059 105.399 0.075
201808 0.039 106.031 0.049
201811 0.009 105.478 0.011
201902 0.006 106.268 0.008
201905 0.022 107.927 0.027
201908 0.048 108.085 0.060
201911 0.004 107.769 0.005
202002 0.014 108.559 0.017
202005 0.013 107.532 0.016
202008 0.045 108.243 0.056
202011 0.099 108.796 0.122
202102 0.047 109.745 0.057
202105 0.040 111.404 0.048
202108 0.006 112.668 0.007
202111 0.002 113.932 0.002
202202 0.005 115.986 0.006
202205 0.017 120.016 0.019
202208 0.019 120.569 0.021
202211 0.016 121.675 0.018
202302 0.003 122.070 0.003
202305 0.012 124.045 0.013
202308 0.004 125.389 0.004
202311 0.017 125.468 0.018
202402 0.013 125.468 0.014
202405 0.006 127.601 0.006
202408 0.005 127.838 0.005
202411 0.011 127.838 0.012
202502 0.010 128.786 0.010
202505 0.010 129.813 0.010
202508 0.009 130.208 0.009
202511 0.000 130.682 0.000
202602 0.001 131.077 0.001
202605 0.000 134.001 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued. The current stock price of $0.54 is trading 46% above its estimated GF Value™ of $0.37. GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.

Key valuation signals for LEXX:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $0.37 vs. price of $0.54 (46% above fair value)
  • GF Score™: 22/100 with 4 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
22GF Score

Get the complete analysis for LEXX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$0.37
GF Value